Tiziana has a fully human therapeutic monoclonal antibody, foralumab, currently being developed for nasal, inhaled and oral delivery to treat autoimmune disease and COVID-19; it is the only fully human anti-CD3 monoclonal. Precision Biosciences, Tiziana’s new US partner, is developing “off-the-shel
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
New use for foralumab in CAR T-cell therapy
- Published:
06 Sep 2021 -
Author:
Robin Davison | John Savin PhD -
Pages:
4
Tiziana has a fully human therapeutic monoclonal antibody, foralumab, currently being developed for nasal, inhaled and oral delivery to treat autoimmune disease and COVID-19; it is the only fully human anti-CD3 monoclonal. Precision Biosciences, Tiziana’s new US partner, is developing “off-the-shel